Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck - Wikidata - wikimedia - TriplyDB

Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck

Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck

http://www.wikidata.org/entity/Q35640310

about

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer Calmodulin protects Aurora B on the midbody to regulate the fidelity of cytokinesis.Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs Aurora kinases in head and neck cancer Aurora kinases: novel therapy targets in cancers Aurora-A signaling is activated in advanced stage of squamous cell carcinoma of head and neck cancer and requires osteopontin to stimulate invasive behavior.The quest to overcome resistance to EGFR-targeted therapies in cancer.Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.Potential impact of human papilloma virus on survival of basaloid squamous carcinoma of the head and neck.A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.A functional cooperativity between Aurora A kinase and LIM kinase1: implication in the mitotic process Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.Depletion of Aurora A leads to upregulation of FoxO1 to induce cell cycle arrest in hepatocellular carcinoma cells.Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer Hypoxia induces TFE3 expression in head and neck squamous cell carcinoma Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism.Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.Phospho-ΔNp63α-dependent regulation of autophagic signaling through transcription and micro-RNA modulation.Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.Bronchogenic cancer: It still exists.The induction of polyploidy or apoptosis by the Aurora A kinase inhibitor MK8745 is p53-dependent.Biologic therapy in head and neck cancer: a road with hurdles.Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase.Deguelin, a Novel Anti-Tumorigenic Agent in Human Esophageal Squamous Cell Carcinoma.High NOTCH1 mRNA Expression Is Associated with Better Survival in HNSCC.

P2860

Q26783412-0A879EB1-0BA5-45F5-98BE-28392837A0C4 Q26784060-BD55324E-E338-42EB-A79E-462FDEA0D845 Q28395452-772D887A-9A23-4D70-BBD4-3A54D63344E8 Q28547522-20E75530-C536-462F-ACB3-4BF8DE3E2472 Q28654389-6EFBB452-5BDF-4866-8089-6E5AFBDA22E6 Q33618929-279A7BB4-AA15-4339-8898-7D43CF3FC214 Q33688594-3CC5E711-FC57-4474-8FB4-EBA8FBAC6367 Q33725976-08531B40-EDF8-4E0C-AD02-1B6FF0F2DA6D Q33917530-B931EC31-4038-4EC3-B0FC-AF9A659D8334 Q34309214-A07D5862-7588-45BC-9792-7BFD5A58975C Q35550280-F429BBC9-AF09-42EF-B29B-8E13E1291B80 Q35799771-019540A5-48D7-494F-8B7A-056B856EBA3C Q35801399-796C1033-1B21-401F-8311-7AAE47F45972 Q35954892-CC213F53-D8DB-44A4-8064-55954424BEDF Q36604655-88F58687-629C-4FCA-A9A5-9DFBE1EB4A14 Q36984851-076C042F-3EC8-4026-AD2B-F9884E18AEB5 Q36998335-F7EAE916-FAD4-4D7C-8E47-15CCD45D21DE Q38118934-EE7849A7-FD27-4709-81C4-40F9A99313F0 Q38979464-CEC12B54-524B-4754-86C5-61EA676AC386 Q39208957-0AA6D5D0-037D-42BE-B913-1320B8C97A9B Q39392171-C37C04D7-B351-4AF7-B760-1548CB8E1C58 Q39475977-B1BAB758-9A9B-4F11-AE5A-5B285DB5C1DD Q41358366-0FD402E9-417E-48D0-99A6-1C699E367749 Q42122240-FF02BC98-26D4-481C-90CB-017DD3E175D5 Q42213295-BB74B5A0-7727-45B5-8C06-63B330923198 Q47426141-9FBEF74D-1BC7-4CA8-ACB4-4E594A019D0C Q52776937-1D754306-D524-4571-9A7C-E7DDBA5948F2 Q54256882-FB49C11B-9857-4E05-B72D-756CB90D059B

P2860

Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck

http://www.wikidata.org/entity/Q35640310

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@ast

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@en

type

label

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@ast

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@en

prefLabel

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@ast

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@en

P1433

Q35640310-6856EA8C-01EE-4AD6-9EC6-B30733A3DE5F

P1476

Q35640310-D3A6382D-9410-4F66-A78B-7F238559BE14

P2093

Q35640310-0390BAD5-E544-4197-9A88-B5807A9A849F

Q35640310-2C09E15F-BDCA-431B-88A9-6BDC63778F21

Q35640310-3CA8A69E-090B-42F5-BE03-2D850A32A792

Q35640310-5BAE22D6-CD3D-442A-9CA9-6ED61C65232A

Q35640310-5DF28449-1B08-48AC-8F23-235365E0B5D9

Q35640310-72913437-1BF6-4278-B4F6-48F0AC797BED

Q35640310-7DDD0AB2-03DB-48A4-84FA-5AF599A608FF

Q35640310-876A7D5B-17F9-4C4D-BDBD-AC20EE245764

Q35640310-98C02489-CDC8-4EAB-9140-0B8E016F6168

Q35640310-9E0FDD73-69A1-4199-9DE2-428B8936F15B

P2860

Q35640310-01E5F252-CB61-4AA6-9B0E-8654A82B59F9

Q35640310-052CEC6A-F9AE-48A8-B2E9-D33081863C9C

Q35640310-0C3D1A05-BB14-4636-AB96-76E7E7552CD1

Q35640310-0F35FC1B-174C-42DE-8F89-5945925F44B1

Q35640310-1C918299-5E6D-4CE9-BD1A-C2DAC308C0FC

Q35640310-2AA1C021-4F23-4391-8586-05BBBF4692B1

Q35640310-3CE721B2-1DC6-482E-9965-82DD841FD80D

Q35640310-3EF45703-902C-42CC-A921-4900DF1D6605

Q35640310-48082DC4-0BBB-475E-AB16-467C58066876

Q35640310-5617BC46-C924-49C0-98C8-B474138F41E7

P304

Q35640310-E0FEBE65-D8B3-4D84-BA4D-A72A9BFDC25B

P31

Q35640310-AB4A4E0C-4507-46C7-BA7E-7A9F00C2A386

P356

Q35640310-407C4650-3759-4FFB-B28F-6A0771BE6B96

P407

Q35640310-BCEBE241-4489-4852-AA54-9B7E8055E408

P433

Q35640310-0484A80C-C111-479F-8968-7E64AA8B5FEC

P478

Q35640310-95AFDB7A-2D5E-4CA7-9ACD-B70459A05EEB

P577

Q35640310-ABB1463F-B23B-48AE-A61F-E53C5BF141A4

P5875

Q35640310-A342005B-CFD6-4BA3-A061-E3038C22708F

P698

Q35640310-38BC2901-F0E5-42A6-99A2-BB8DDB5C7349

P921

Q35640310-44355599-4DF7-4CD5-B768-64617DC2D886

P932

Q35640310-142E09BE-4498-499B-8522-0D1544841FF1

P356

P1433

P1476

Aurora kinase inhibition overc ...... ll cancer of the head and neck

@en

P2093

Alexander Hoellein

http://www.w3.org/2001/XMLSchema#string

Anja Baumgart

http://www.w3.org/2001/XMLSchema#string

Anja Pickhard

http://www.w3.org/2001/XMLSchema#string

Christian Peschel

http://www.w3.org/2001/XMLSchema#string

Fabienne von Keitz

http://www.w3.org/2001/XMLSchema#string

Guido Piontek

http://www.w3.org/2001/XMLSchema#string

Henning Bier

http://www.w3.org/2001/XMLSchema#string

Martina Rudelius

http://www.w3.org/2001/XMLSchema#string

Stefan Wagenpfeil

http://www.w3.org/2001/XMLSchema#string

Stephanie Schoeffmann

http://www.w3.org/2001/XMLSchema#string

P2860

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival.

Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.

Microtubules as a target for anticancer drugs

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state.

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

The EGFR as a target for anticancer therapy--focus on cetuximab.

P304

599-609

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.311

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51593992

http://www.w3.org/2001/XMLSchema#string

P698

21865609

http://www.w3.org/2001/XMLSchema#string

P921

P932

3248211

http://www.w3.org/2001/XMLSchema#string